{"contentid": 488649, "importid": NaN, "name": "Trial results for Farxiga in COVID-19 detailed at ACC 2021", "introduction": "Detailed results from the Phase III DARE-19 trial, testing AstraZeneca's (LSE: AZN) SGLT2 blocker Farxiga (dapagliflozin) in COVID-19, show no significant benefit for patients.", "content": "<p>Detailed results from the Phase III DARE-19 trial, testing AstraZeneca's (LSE: AZN) SGLT2 blocker Farxiga (dapagliflozin) in COVID-19, show no significant benefit for patients.</p>\n<p>The presentation, at the annual meeting of the American College of Cardiology (ACC), follows high-level results released in early April.</p>\n<p>The study, which assesses the potential of the diabetes drug to help people who have been hospitalized with COVID-19, was conducted in partnership with Saint Luke&rsquo;s Mid America Heart Institute.</p>\n<p>The results show that 11.2% of those given Farxiga died or suffered organ failure, compared with 13.8% of those given the placebo. A secondary endpoint of recovery returned similar results between the two arms.</p>\n<p>While the outcome does not meet the bar for statistical significance, the data do point favorably towards some potential benefit in terms of organ protection.</p>\n<p>Principal investigator Mikhail Kosiborod said the trial provided &ldquo;important data on the potential benefits and risks of using SGLT2 inhibitors to treat hospitalized patients&rdquo; with the disease.</p>\n<p>He added: &ldquo;While the trial did not achieve statistical significance, the findings are very interesting and valuable, and will inform future clinical science. Also, of importance, we learned that dapagliflozin&rsquo;s well-established safety profile was consistent in DARE-19.&rdquo;&nbsp;</p>", "date": "2021-05-17 14:12:00", "meta_title": NaN, "meta_keywords": "results, trial, COVID-, Farxiga, detailed, show, benefit, DARE-, patients, SGLT, Phase, significant, dapagliflozin, blocker, AstraZeneca, testing, potentia", "meta_description": "Detailed results from the Phase III DARE-19 trial, testing AstraZeneca's (LSE: AZN) SGLT2 blocker Farxiga (dapagliflozin) in COVID-19, show no significant benef", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-17 14:11:59", "updated": "2021-05-17 14:15:16", "access": NaN, "url": "https://www.thepharmaletter.com/article/trial-results-for-farxiga-in-covid-19-detailed-at-acc-2021", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astrazeneca_big-1.jpg", "image2id": "astrazeneca_small-2.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "ACC, Conferences", "geography_tag": "UK", "company_tag": "AstraZeneca", "drug_tag": "Farxiga", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-17 14:12:00"}